Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric <scp>BCP</scp>‐<scp>ALL</scp> After Tisagenlecleucel: A Case Series
InO can be used successfully and safely for the treatment of CD22<sup>POS</sup> BCP-ALL relapse after tisagenlecleucel as a bridge to allo-HSCT in heavily pretreated pediatric patients.
Authors
- Nancy Boeckx
- Heidi Segers (ORCID: https://orcid.org/0000-0002-3604-7850)
- Anne Uyttebroeck (ORCID: https://orcid.org/0000-0001-5644-424X)
- Margo Aertgeerts (ORCID: https://orcid.org/0000-0003-0734-380X)
- Marleen Renard
Institutions
- Universitair Ziekenhuis Leuven (BE)
- VIB-KU Leuven Center for Cancer Biology (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cnr2.70177
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitair Ziekenhuis Gent
- KU Leuven
- Universiteit Gent
- Stichting Tegen Kanker